---
layout: default
title: Actaea Spicata Root Ammonium Benzoate Arnica Monta
parent: 僅模型預測 (L5)
nav_order: 150
evidence_level: L5
indication_count: 0
---

# Actaea Spicata Root Ammonium Benzoate Arnica Monta
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex: TxGNN Repurposing Analysis Incomplete

## One-Sentence Summary

This candidate consists of a 21-ingredient homeopathic/botanical combination product (including Arnica Montana, Echinacea Purpurea, Bryonia Alba Root, and others) with no DrugBank identifier, no regulatory approval records in Taiwan or the US, and no original indication on file.
Because TxGNN requires a mapped DrugBank ID and a defined single-entity drug node, **no repurposing predictions could be generated** for this submission.
Without predictions, clinical trial evidence, or safety data, a full evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unknown — no regulatory approval records found |
| Predicted New Indication | Not available — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Cannot be determined |
| US Market Status | Not marketed (0 NDAs on file) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

TxGNN operates on the knowledge graph by matching a single drug entity to a DrugBank node and then traversing disease-gene-drug relationships to produce repurposing scores. This submission presents three structural barriers that prevented any prediction from being produced:

**1. No DrugBank ID.** The drug field lists 21 separate botanical/homeopathic ingredients rather than a single unified compound. DrugBank lookup returned a result count of 1 (query log entry 3), but no DrugBank ID was successfully resolved for the combined entity. Individual ingredients such as Quinine Sulfate, Berberine (from *Berberis vulgaris*), or Echinacea have their own DrugBank entries, but the combination as a whole does not.

**2. No mapped disease node.** Because `original_indications` is empty, there is no anchor disease from which TxGNN can compute graph distance or similarity to candidate repurposing targets. The model cannot infer a starting point.

**3. Homeopathic formulation design.** Products composed of ultra-diluted multi-botanical extracts (e.g., *Arnica montana*, *Pulsatilla vulgaris*, *Rhododendron* spp.) typically lack pharmacokinetic profiles or receptor-binding data that the knowledge graph depends on. This limits computational tractability regardless of the number of ingredients.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

*(No predicted indication is available from which to construct a ClinicalTrials.gov query.)*

---

## Literature Evidence

Currently no related literature available.

*(Literature evidence search requires a predicted indication target. None was generated.)*

---

## US Market Information

No US regulatory authorizations on file for this combination product.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on individual ingredients:** Several components in this formulation carry known safety considerations independent of this submission:
> - **Comfrey Root** (*Symphytum officinale*) contains pyrrolizidine alkaloids associated with hepatotoxicity; systemic use is restricted in multiple jurisdictions.
> - **Chelidonium majus** has hepatotoxicity case reports in the literature.
> - **Quinine Sulfate** carries FDA black-box warnings for use outside malaria; associated with thrombocytopenia and cardiac arrhythmia.
> - **Toxicodendron pubescens** (Poison Oak) may cause severe contact sensitization reactions.
> - **Bryonia Alba Root** contains cucurbitacins with cytotoxic properties at non-homeopathic doses.
>
> A formal ingredient-by-ingredient safety assessment is recommended before any clinical development path is considered.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN could not generate any repurposing predictions because the submission lacks a resolvable DrugBank ID, an original disease indication, and a single-entity drug structure compatible with the knowledge graph. There is therefore no computational or evidential basis on which to evaluate a new indication.

**To proceed, the following is needed:**

1. **Resolve the drug entity problem** — Decide whether to evaluate the combination as a whole or select one or more individual active ingredients (e.g., Quinine Sulfate, Berberine) for separate TxGNN submissions with their own DrugBank IDs.
2. **Define an original indication** — Identify what therapeutic claim this combination is intended or historically used for (e.g., musculoskeletal pain, arthritis), to anchor the graph traversal.
3. **Obtain regulatory status** — Confirm whether any component or the combination holds an OTC homeopathic monograph status (e.g., under FDA homeopathic drug guidance) or a foreign market approval, and document the approved indication text.
4. **Conduct MOA assessment** — For any individual ingredient selected for further analysis, retrieve DrugBank mechanism of action data to support a mechanistic rationale.
5. **Safety review** — Commission a formal ingredient-level safety dossier covering hepatotoxicity risk (Comfrey, Chelidonium), cardiac risk (Quinine), and sensitization risk (Toxicodendron) before any clinical development step.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

